Literature DB >> 17656183

Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents.

Young A Han1, Mukul Singh, Brij B Saxena.   

Abstract

OBJECTIVES: Construction of vaginal rings to deliver nonhormonal contraceptives and 3'-azido-3'-deoxythymidine (AZT) as an anti-HIV agent and determination of their daily release and efficacy in vitro.
MATERIALS AND METHODS: Intravaginal rings of 0.5-0.7 cm rim and 5-5.5 cm in diameter were cast in the molds. The rings were composed of biosoluble acacia gum or nonbiodegradable hydrogel of 2-hydroxyethyl methacrylate (HEMA) and sodium methacrylate (SMA) [P(HEMA-co-SMA)]. The rings were impregnated with nonhormonal contraceptives such as ferrous gluconate to cause spermiostasis, l-ascorbic acid to increase the viscosity of the cervical mucus, and pharmalytes of pH 4-5 or AZT.
RESULTS: The daily release rate of nonhormonal contraceptives as well as AZT from the rings was efficacious in vitro. Cumulative effect of nonhormonal contraceptives showed complete spermiostasis within 30 s up to 10 and 28 days, respectively. Daily release of AZT from both rings was also likely to be efficacious to inhibit HIV proliferation in vitro for 10 and 28 days, respectively.
CONCLUSION: The data indicate that the rings described here can be developed for intravaginal delivery of nonhormonal contraceptives and/or anti-HIV agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656183     DOI: 10.1016/j.contraception.2007.04.006

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  13 in total

1.  Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections.

Authors:  David R Friend
Journal:  Drug Deliv Transl Res       Date:  2011-06       Impact factor: 4.617

2.  An intravaginal ring for the simultaneous delivery of multiple drugs.

Authors:  Marc M Baum; Irina Butkyavichene; Joshua Gilman; Sean Kennedy; Etana Kopin; Amanda M Malone; Cali Nguyen; Thomas J Smith; David R Friend; Meredith R Clark; John A Moss
Journal:  J Pharm Sci       Date:  2012-05-22       Impact factor: 3.534

3.  In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward?

Authors:  Nina Derby; Thomas Zydowsky; Melissa Robbiani
Journal:  Expert Rev Anti Infect Ther       Date:  2013-01       Impact factor: 5.091

4.  In situ-forming and pH-responsive hydrogel based on chitosan for vaginal delivery of therapeutic agents.

Authors:  Esmat Jalalvandi; Amin Shavandi
Journal:  J Mater Sci Mater Med       Date:  2018-10-22       Impact factor: 3.896

5.  The optimization of an intravaginal ring releasing progesterone using a mathematical model.

Authors:  Ignacio M Helbling; Juan C D Ibarra; Julio A Luna
Journal:  Pharm Res       Date:  2013-10-18       Impact factor: 4.200

6.  Development of Hormonal Intravaginal Rings: Technology and Challenges.

Authors:  Fojan Rafiei; Hadi Tabesh; Shayan Farzad; Farah Farzaneh; Maryam Rezaei; Fateme Hosseinzade; Khosrow Mottaghy
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-07-13       Impact factor: 2.915

7.  Drug-eluting fibers for HIV-1 inhibition and contraception.

Authors:  Cameron Ball; Emily Krogstad; Thanyanan Chaowanachan; Kim A Woodrow
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

8.  Preparation and evaluation of intravaginal ring containing drospirenone.

Authors:  Ying Zhang; Chun-Xiao Li; Mei-Ying Ning; Xue-Yan Duan; Ying Liu
Journal:  Adv Pharmacol Sci       Date:  2013-01-17

9.  Vaginal rings for delivery of HIV microbicides.

Authors:  R Karl Malcolm; Susan M Fetherston; Clare F McCoy; Peter Boyd; Ian Major
Journal:  Int J Womens Health       Date:  2012-11-20

Review 10.  Contraception and HIV infection in women.

Authors:  Oskari Heikinheimo; Pekka Lähteenmäki
Journal:  Hum Reprod Update       Date:  2008-11-01       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.